DAIICHI SANKYO CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,522 JPY | +0.73% |
|
+2.60% | +42.69% |
| May. 15 | Merck to present new oncology data | CF |
| May. 15 | IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 1,602B 10.28B | Sales 2025 * | 1,767B 11.34B | Capitalization | 10,509B 67.42B |
|---|---|---|---|---|---|
| Net income 2024 | 201B 1.29B | Net income 2025 * | 195B 1.25B | EV / Sales 2024 | 5.72 x |
| Net cash position 2024 * | 556B 3.57B | Net cash position 2025 * | 603B 3.87B | EV / Sales 2025 * | 5.61 x |
| P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
53.4
x | Employees | 17,435 |
| Yield 2024 |
1.05% | Yield 2025 * |
1.09% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Co., Ltd.
More recommendations
More press releases
More news
| 1 day | -0.07% | ||
| 1 week | +1.73% | ||
| Current month | +2.13% | ||
| 1 month | +23.30% | ||
| 3 months | +12.42% | ||
| 6 months | +37.36% | ||
| Current year | +41.48% |
1 week
5 347.00
5 508.00
1 month
4 481.005 520.00
Current year
3 847.005 520.00
1 year
3 566.005 520.00
3 years
1 981.005 520.00
5 years
1 731.005 520.00
10 years
518.675 520.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.16% | 19 M€ | +11.14% | ||
| 4.18% | 240 M€ | +20.06% | ||
| 3.32% | 174 M€ | -.--% | - | |
| 3.32% | 51 M€ | -.--% | - | |
| 3.24% | 14 M€ | +16.87% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 5,522 | +0.73% | 2 605 500 |
| 24-05-16 | 5,482 | -0.07% | 4,052,000 |
| 24-05-15 | 5,486 | +1.31% | 4,593,500 |
| 24-05-14 | 5,415 | -0.13% | 3,316,700 |
| 24-05-13 | 5,422 | +0.69% | 3,101,400 |
Delayed Quote Japan Exchange, May 16, 2024 at 10:09 pm EDT
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,482
JPY
Average target price
5,853
JPY
Spread / Average Target
+6.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.48% | 67.92B | |
| +32.36% | 709B | |
| +30.77% | 595B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B |
- Stock Market
- Equities
- 4568 Stock
